… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
At ProQR science is literally at the heart of what we do. Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments.
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … (SAB) with leaders in inherited retinal disease and RNAtherapy. The SAB members are: James Shannon, MD, Chair of the …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … (SAB) with leaders in inherited retinal disease and RNAtherapy. In February, ProQR announced its participation in …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … 1b/2 trial results of the intravitreal sepofarsen RNAtherapy in LCA10 (encore presentations) Full-field stimulus …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… on track to be reported in H2 2020; Three clinical stage RNA therapies in development for inherited retinal diseases, … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
